Cosunter(SZ:300436) Xin Lang Cai Jing·2025-11-13 05:22Group 1 - The core point of the article highlights the recent performance of Guangshentang, which saw a 5.03% increase in stock price, reaching 109.55 CNY per share, with a trading volume of 812 million CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 17.448 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares, with an estimated floating profit of approximately 3.7178 million CNY [2] - The China Europe Medical Health Mixed A fund was established on September 29, 2016, with a current scale of 16.977 billion CNY, achieving a year-to-date return of 21.25% and a one-year return of 8.97% [2]